Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab vs platinum-based chemotherapy in first-line PD-L1+ NSCLC (China)
CTR20171000Phase 3Terminated
- Sponsor
- Merck KGaA
- Start
- Nov 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of avelumab in non-small cell lung cancer (NSCLC), sponsored by Merck KGaA. Started Nov 2017; status: terminated.
02
Drugs
avelumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20171000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171000.